Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: J Invest Dermatol. 2015 May 27;135(10):2475–2483. doi: 10.1038/jid.2015.198

Figure 6. Tumor size reduction of NRAS mutant xenografts with the MEK/Plk1 combination.

Figure 6

(a) Treatment of established mouse xenografts showed tumor size reduction after initiation of treatment (day 0) with the combination of a MEKi (2 mg*kg−1*d−1) and Plk1i (50 mg*kg−1*week−1), but not with either MEKi or Plk1i alone. (cell lines: Sk-Mel-2, WM3670; MEKi: JTP-74057; Plk1i: BI6727; n=4) Results are displayed as the mean change in tumor volume at indicated time points ± SD. (b) Corresponding immunoblot analyses of mouse tumors after 3 weeks of treatment with the indicated conditions.